Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell Disease
NCT05640271Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in acute chest syndrome (ACS), sponsored by University of Chicago. Started Apr 2023; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
acute chest syndrome (ACS)
Beyond the preview
Go deeper on NCT05640271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640271.